IP Library › Granted Patent US 9,062,073

Granted Patent B2

US 9,062,073 · App. 14/119,405 · Granted Jun 23, 2015

Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor

Inventors: Alan S. Verkman (San Francisco, CA); David S. Snyder (Davis, CA)

Assignee: The Regents of the University of California

C07D498/14 C07D487/14

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,062,073
App. No.: 14/119,405
Granted: Jun 23, 2015
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are benzopyrimido-pyrrolo-oxazine-dione (BPO) compounds and pyrimido-pyrrolo-quinoxalinedione (PPQ) compounds, and compositions comprising these compounds, that inhibit cystic fibrosis transmembrane conductance regulator (CFTR) mediated ion transport and that are useful for treating diseases and disorders associated with aberrantly increased CFTR chloride channel activity, such as polycystic kidney disease and secretory diarrheas. The compounds and compositions comprising the compounds described herein may be used for inhibiting expansion or preventing formation of cysts in persons who have polycystic kidney disease.

Claims (115)

1. A compound having the following structure (I):

as an isolated enantiomer or a racemic mixture of enantiomers, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide, thereof, wherein:

m is 1, 2, 3, or 4;

n is 1, 2, 3, 4 or 5;

p is an integer from 0 to 4;

q is an integer from 1 to 4;

R 1 at each occurrence is the same or different and independently H, halo, haloalkyl, C 1 -C 6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 1a at each occurrence is the same or different and independently H, halo, haloalkyl, C 1 -C 6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 2a and R 2b are each the same or different and independently H, or C 1 -C 6 alkyl;

R 4a is —OR 7 , —NR 7 R 8 , —O(CH 2 ) q —OC(O)R 7 , or an amino acid residue;

R 7 and R 8 are each the same or different and independently H, C 1 -C 20 alkyl, a saccharide, or an amino acid residue; and

Z is aryl or heteroaryl,

wherein the amino acid residue is selected from residues of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutylic acid, cirtulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone, tert-butylglycine, 3,5-dibromotyrosine, 3,5-diiodotyrosine, glycosylated threonine, glyclosylated serine, and glycosylated asparagine.

2. The compound of claim 1 , wherein R 2a and R 2b are each methyl, and Z is optionally substituted furanyl or optionally substituted thienyl, and the compound has the following structure (IA) or (IB), respectively:

as an isolated enantiomer or a racemic mixture of enantiomers, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein:

m is 1, 2, 3, or 4;

n is 1, 2, 3, 4 or 5;

p is an integer from 0 to 4;

q is an integer from 1 to 4;

R 1 at each occurrence is the same or different and independently H, halo, haloalkyl, C 1-6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 1a at each occurrence is the same or different and independently H, halo, haloalkyl, C 1-6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 4a is —OR 7 , —NR 7 R 8 , —O(CH 2 ) q —OC(O)R 7 , or an amino acid residue;

R 5 is H, halo, or C 1-6 alkyl;

R 6 is H, halo, C 1-6 alkyl, or C 1-6 haloalkyl; and

R 7 and R 8 are each the same or different and independently H, C 1-20 alkyl, a saccharide, or an amino acid residue,

3. The compound of claim 1 , wherein R 2a and R 2b are each methyl, p is 0, R 4a is —OR 7 is Z is optionally substituted furanyl, n is 1 and R 1 is meta to the linking carbon and the compound has the following structure (IA1):

wherein:

R 1 is H, halo, or C 1-6 alkyl;

R 2 and R 3 are each the same or different and independently H, halo, —NO 2 , C 1-6 alkyl, tetrazolyl, —S(O) 2 OR 7 , or —C(═O)OR 7 ;

R 5 is H, halo, or C 1-6 alkyl;

R 6 is halo, C 1 -C 6 alkyl, or C 1-6 haloalkyl; and

R 7 is H, C 1-6 alkyl, a saccharide, or an amino acid residue, selected residues of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutylic acid, cirtulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone, tert-butylglycine, 3,5-dibromotyrosine, 3,5-diiodotyrosine, glycosylated threonine, glyclosylated serine, and glycosylated asparagine.

4. The compound of claim 1 , wherein R 2a and R 2b are each methyl, p is 0, R 4a is —OR 7 , Z is optionally substituted thienyl, n is 1 and R 1 is meta to the linking carbon, and the compound has the following structure (IB1):

wherein:

R 1 is H, halo, or C 1-6 alkyl;

R 2 and R 3 are each the same or different and independently H, halo, —NO 2 , C 1-6 alkyl, tetrazolyl, —S(O) 2 OR 7 , or —C(═O)OR 7 ;

R 5 is H, halo, or C 1-6 alkyl;

R 6 is halo, C 1-6 alkyl, or C 1-6 haloalkyl; and

R 7 is H, C 1-6 alkyl, a saccharide, or an amino acid residue selected from residues of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutylic acid, cirtulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, methionine sulfone, tert-butylglycine, 3,5-dibromotyrosine, 3,5-diiodotyrosine, glycosylated threonine, glyclosylated serine, and glycosylated asparagine.

5. The compound of claim 1 , wherein R 2a and R 2b are each methyl, and Z is optionally substituted phenyl, and the compound has the following structure (IC):

as an isolated enantiomer or a racemic mixture of enantiomers, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein:

m is 1, 2, 3, or 4;

n is 1, 2, 3, 4 or 5;

p is an integer from 0 to 4;

q is an integer from 1 to 4;

t is 1, 2, 3, 4 or 5;

R 1 at each occurrence is the same or different and independently H, halo, haloalkyl, C 1-6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 1a at each occurrence is the same or different and independently H, halo, haloalkyl, C 1-6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 1b at each occurrence is the same or different and independently H, halo, —OH, —NO 2 , C 1-6 alkyl, C 2-6 alkenyl, or C 1-6 alkoxy;

R 4a is —OR 7 , —NR 7 R 8 , —O(CH 2 ) q —OC(O)R 7 , or an amino acid residue;

R 7 and R 8 are each the same or different and independently H, C 1-20 alkyl, a saccharide, or an amino acid residue,

6. The compound of claim 1 , wherein R 2a and R 2b are each methyl, p is 0, R 4a is —OR 7 , n is 1, and R 1 is meta to the linking carbon and the compound has the following structure:

wherein:

R 1 is H, halo, or C 1 -C 6 alkyl;

R 2 and R 3 are each the same or different and independently H, halo, —NO 2 , C 1-6 alkyl, tetrazolyl, —S(O) 2 OR 7 , or —C(═O)OR 7 ;

t is 1, 2, 3, 4 or 5;

R 1b at each occurrence is the same or different and independently H, halo, —OH, —NO 2 , C 1-6 alkoxy, or C 1-6 alkyl; and

7. A compound having the following structure (II):

as an isolated enantiomer or a racemic mixture of enantiomers, or as a pharmaceutically acceptable salt, hydrate, solvate, or N-oxide thereof, wherein:

m is 1, 2, 3, or 4;

n is 1, 2, 3, 4 or 5;

p is an integer from 0 to 4;

q is an integer from 1 to 4;

X is O or S;

R 1 at each occurrence is the same or different and independently H, halo, haloalkyl, C 1-6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 1a at each occurrence is the same or different and independently H, halo, haloalkyl, C 1-6 alkyl, —(CH 2 ) p —C(O)—R 4a , —S(O) 2 R 4a , —NO 2 , or tetrazolyl;

R 2a and R 2b are each the same or different and independently H or C 1-6 alkyl;

R 4a is —OR 7 , —NR 7 R 8 , —O(CH 2 ) q —OC(O)R 7 , an amino acid residue;

R 4 is H, —N(═O), C 1-6 alkyl, or haloalkyl;

R 5 is H, halo, or C 1-6 alkyl;

R 6 is halo; and

R 7 and R 8 are each the same or different and independently H, C 1 -C 20 alkyl, a saccharide, or an amino acid residue

8. The compound of claim 7 , wherein R 2a and R 2b are each methyl, p is 0, R 4a is —OR 7 , n is 1 and R 1 is meta to the linking carbon, and the compound has the following structure (IIA):

wherein:

X is O or S;

R 1 is H, halo, or C 1-3 alkyl;

R 2 is H, halo, —NO 2 , or —C(═O)OR 7 ;

R 3 is H or —NO 2 ;

R 4 is —N(═O), C 1-3 alkyl, or H;

R 5 is H or C 1-3 alkyl;

R 6 halo; and

R 7 is H, C 1-6 alkyl, a saccharide, an amino acid residue of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, phosphoserine, phosphothreonine, phosphotyrosine, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, gamma-carboxyglutamate, hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, 3-methylhistidine, norvaline, beta-alanine, gamma-aminobutylic acid, cirtulline, homocysteine, homoserine, methyl-alanine, para-benzoylphenylalanine, phenylglycine, proparagylglycine, sarcosine, methionine sulfone tert-butylglycine 3,5-dibromotyrosine, 3,5-diiodotyrosine, glycosylated threonine, glyclosylated serine, and glycosylated asparagine.

9. The compound of claim 1 , wherein (a) each R 1 is H; (b) at least one R 1 is methyl or ethyl; (c) at least one R 1 is methyl and each remaining R 1 is H; or (d) at least one R 1 is ethyl and each remaining R 1 is H.

10. The compound of either claim 1 , wherein m=2 and p=0 and (a) at least one of R 1a is halo, —NO 2 , C 1-3 alkyl, —C(O)—R 4a ; or (b) each of R 1a is H.

11. The compound of claim 5 , wherein (a) each R 1 is H; (b) at least one R 1 is methyl or ethyl; (c) at least one R 1 is methyl and each remaining R 1 is H; or (d) at least one R 1 is ethyl and each remaining R 1 is H.

12. The compound of claim 5 , wherein m=2 and p=0 and (a) at least one of R 1a is halo, —NO 2 , C 1-3 alkyl, —C(O)—R 4a ; or (b) each of R 1a is H.

13. The compound of claim 6 , wherein (a) R 2 is H, halo, —NO 2 , or —C(═O)OR 7 , wherein R 7 is H or C 1 -C 6 alkyl; (b) R 2 is H, halo, —NO 2 , or —C(═O)OR 7 , wherein R 7 is H, —CH 3 , —CH 2 CH 3 , or —CH 2 CH 2 CH 3 ; (c) R 2 is H, chloro, or —NO 2 ; (d) R 2 is —C(═O)OR 7 , wherein R 7 is H, —CH 3 , or —CH 2 CH 3 ; or (e) R 2 is chloro.

14. The compound of claim 5 , wherein (a) t=2 and each R 1b is the same or different and independently H, —OH, halo, —NO 2 , C 1-3 alkyl, or C 1-3 alkoxy; or

(b) t=1 and R 1b is —OH, halo, —NO 2 , C 1-3 alkyl, or

(d) t=1 and R 1b is —OH, chloro, flouro, —NO 2 , methyl, or methooxy; (c) each R 1b is H.

15. The compound of claim 3 wherein (a) R 2 is H, halo, —NO 2 , or —C(═O)OR 7 , wherein R 7 is H or C 1-6 alkyl; (b) R 2 is H, halo, —NO 2 , or —C(═O)OR 7 , wherein R 7 is H, —CH 3 , —CH 2 CH 3 , or —CH 2 CH 2 CH 3 ; (c) R 2 is H, chloro, or —NO 2 ; (d) R 2 is —C(═O)OR 7 , wherein R 7 is H, —CH 3 , or —CH 2 CH 3 ; or (e) R 2 is chloro.

16. The compound of claim 4 wherein (a) R 2 is H, halo, —NO 2 , or —C(═O)OR 7 , wherein R 7 is H or C 1-6 alkyl; (b) R 2 is H, halo, —NO 2 , or —C(═O)OR 7 , wherein R 7 is H, —CH 3 , —CH 2 CH 3 , or —CH 2 CH 2 CH 3 ; (c) R 2 is H, chloro, or —NO 2 ; (d) R 2 is —C(═O)OR 7 , wherein R 7 is H, —CH 3 , or —CH 2 CH 3 ; or (e) R 2 is chloro.

17. The compound of claim 2 , wherein (a) each R 1 is H; (b) at least one R 1 is methyl or ethyl; (c) at least one R 1 is methyl and each remaining R 1 is H; or (d) at least one R 1 is ethyl and each remaining R 1 is H.

18. The compound of claim 7 , wherein (a) each R 1 is H; (b) at least one R 1 is methyl or ethyl; (c) at least one R 1 is methyl and each remaining R 1 is H; or (d) at least one R 1 is ethyl and each remaining R 1 is H.

19. The compound of claim 2 , wherein m+2 and p=0 and (a) at least one of R 1a is halo, —NO 2 , C 1 -C 3 alkyl, —C(O)—R 4a ; or (b) each of R 1a is H.

20. The compound of claim 7 , wherein m=2 and p=0 and (a) at least one of R 1a is halo, —NO 2 , C 1-3 alkyl, —C(O)—R 4a ; or (b) each of R 1a is H.

21. The compound of claim 2 , wherein R 6 is chloro, bromo, or iodo.

22. The compound of claim 1 , wherein the compound has any one of the following structures:

23. The compound of claim 7 , wherein the compound has any one of the following structures:

24. The compound of claim 1 , wherein the compound is an isolated enantiomer in R form.

25. The compound of claim 24 wherein the compound is 6R-(5-Bromofuran-2-yl)-7,9-dimethyl-8,10-dioxo-11-phenyl-7,8,9,10-tetrahydro-6H-benzo [b]pyrimido[4′,5′:3,4]pyrrolo [1,2-d][1,4]oxazine-2-carboxylic acid.

26. The compound of claim 1 , wherein the compound is an isolated enantiomer in S form.

27. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically suitable excipient.

28. A method for inhibiting cyst formation or inhibiting cyst enlargement, said method comprising contacting (a) a cell that comprises CFTR and (b) the pharmaceutical composition of claim 27 , under conditions and for a time sufficient that permit CFTR and the compound to interact, wherein the compound inhibits CFTR-mediated ion transport.

29. A method for treating a disease, condition, or disorder that is treatable by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR)-mediated ion transport, said method comprising administering to a subject the pharmaceutical composition of claim 27 , thereby inhibiting CFTR-mediated ion transport.

30. The method of claim 29 , wherein the disease, condition, or disorder is selected from polycystic kidney disease, aberrantly increased intestinal fluid secretion, and secretory diarrhea.

31. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically suitable excipient.

32. A method for inhibiting cyst formation or inhibiting cyst enlargement, said method comprising contacting (a) a cell that comprises CFTR and (b) the pharmaceutical composition of claim 31 , under conditions and for a time sufficient that permit CFTR and the compound to interact, wherein the compound inhibits CFTR-mediated ion transport.

33. A method for treating a disease, condition, or disorder that is treatable by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR)-mediated ion transport, said method comprising administering to a subject the pharmaceutical composition of claim 31 , thereby inhibiting CFTR-mediated ion transport.

34. The method of claim 33 , wherein the disease, condition, or disorder is selected from polycystic kidney disease, aberrantly increased intestinal fluid secretion, and secretory diarrhea.

Assignments (2)

CONFIRMATORY LICENSE Recorded Dec 12, 2017

From: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT

Reel/Frame 044839/0017 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2014

From: VERKMAN, ALAN S.; SNYDER, DAVID S.

To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Reel/Frame 032162/0905 →

Continuity (2)

Provisional Application 61491151 · May 27, 2011

Related Publication 20140080821A1 · Mar 20, 2014